RES Group

RES Group Inc., a spin-off of MIT, is a privately held company based in Broomfield, Colorado. The company employs 24 people and generates an annual revenue of $4 million. Founded in 2001, RES Group specializes in Quantitative Systems Pharmacology (QSP) modeling, aiming to accelerate and de-risk drug development processes. RES Group provides a variety of services centered around their expertise in mechanistic QSP modeling. These services include First-in-Human (FIH) dose projections for IND applications, toxicity projections for regulatory submissions, and support for early-stage drug development. Their services are primarily utilized by biotechnology and pharmaceutical companies. RES Group's approach to drug development, known as Model Informed Drug Development (MIDD), has proven successful in numerous projects. Notably, their work with Takeda on an application for an ultra-rare blood clotting disorder was recently approved by the FDA. Additionally, their human dose projection for a Duchenne muscular dystrophy gene therapy candidate was accepted in an IND clearance by the FDA. For further information or inquiries, please visit RES Group's website at resgroupinc.com/predictive-science.